Dr Reddys Laboratories Ltd

Dr. Reddy's Laboratories Ltd. is a multinational pharmaceutical company founded in 1984. Headquartered in Hyderabad, India, it also maintains a U.S. headquarters in East Brunswick, New Jersey. The company is publicly traded on the BSE, NSE, and the New York Stock Exchange (NYSE: RDY). Dr. Reddy's employs over 24,000 people globally and reported revenues of approximately $3.6 billion for the fiscal year ending in March 2025.

The company operates as an integrated pharmaceutical firm with three main business segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Its product portfolio includes over 190 medications and 60 active pharmaceutical ingredients (APIs) for drug manufacturing. Dr. Reddy's develops and markets a wide range of products across therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. They offer generic drugs, branded generics, over-the-counter products, biosimilars, and diagnostic kits.

As an operating company in the pharmaceutical industry, Dr. Reddy's Laboratories is primarily a defendant in patent litigation, typically in suits brought by brand-name drug manufacturers. The provided case data, showing the company as a defendant in one recent suit and as a plaintiff in none, is consistent with the legal challenges often faced by generic drug manufacturers. This type of litigation, commonly related to abbreviated new drug applications (ANDAs), is a standard part of the business model for companies seeking to market generic versions of patented medicines.

The single tracked case, Astellas US LLC et al. v. Dr Reddys Laboratories Ltd, filed in the District of New Jersey, exemplifies this posture. This jurisdiction is a common venue for pharmaceutical patent litigation. Such cases typically involve allegations of patent infringement by the original drug creator against the generic manufacturer. The outcome of these legal battles often determines when a generic version of a drug can enter the market.